DIM Stock Analysis: Sartorius Stedim Biotech | PA
Medical Instruments & Supplies | PA, France | Market Cap: 21.288m EUR | 12M Return: 11.6% | FR0013154002 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.4M
EPS Trend: 14.1%
Qual. Beats: 0
Rev. Trend: 66.3%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Its product portfolio spans cell lines, cell culture media, bioreactors, reagents, separation and purification tools, storage and transport systems, fluid management services, sensors, chromatography systems, lab and process software, and water purification systems. The company serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. It is headquartered in Aubagne, France, was incorporated in 1978, and operates as a subsidiary of Sartorius AG.
As a key supplier to the biopharmaceutical sector, Sartorius Stedim is widely recognized as a leading provider of single-use technologies used in the production of biologics, vaccines, and advanced therapies. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focused on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to address oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions.
- Bioprocess consumables demand softens amid biotech funding pullback
- Margin compression persists from pricing pressure and elevated input costs
- Capacity expansion capex weighs on near-term free cash flow
| Net Income: 292.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -3.19 > 1.0 |
| NWC/Revenue: 6.20% < 20% (prev 29.73%; Δ -23.53% < -1%) |
| CFO/TA 0.08 > 3% & CFO 615.1m > Net Income 292.6m |
| Net Debt (2.37b) to EBITDA (886.6m): 2.67 < 3 |
| Current Ratio: 1.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.3m) vs 12m ago -1.99% < -2% |
| Gross Margin: 44.87% > 18% (prev 44.63%; Δ 0.24% > 0.5%) |
| Asset Turnover: 37.03% > 50% (prev 34.84%; Δ 2.19% > 0%) |
| Interest Coverage Ratio: 3.15 > 6 (EBIT TTM 563.3m / Interest Expense TTM 179.1m) |
| A: 0.02 (Total Current Assets 1.35b - Total Current Liabilities 1.17b) / Total Assets 7.92b |
| B: 0.35 (Retained Earnings 2.79b / Total Assets 7.92b) |
| C: 0.07 (EBIT TTM 563.3m / Avg Total Assets 8.11b) |
| D: 1.15 (Book Value of Equity 4.24b / Total Liabilities 3.67b) |
| Altman-Z'' = 2.98 = A |
| DSRI: 1.20 (Receivables 328.2m/263.8m, Revenue 3.01b/2.90b) |
| GMI: 0.99 (GM 44.63% / 44.87%) |
| AQI: 1.04 (AQ_t 0.57 / AQ_t-1 0.55) |
| SGI: 1.04 (Revenue 3.01b / 2.90b) |
| TATA: -0.04 (NI 292.6m - CFO 615.1m) / TA 7.92b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at EUR 212.80 with a total of 75,552 shares traded. Over the past week, the price has changed by +2.21%, over one month by +11.65%, over three months by +18.49% and over the past year by +11.58%.
Current recommended Stop Loss: 204.20 (which is 4% or 1.2 ATR below the current price).
Sartorius Stedim Biotech has no consensus analysts rating.
P/E Trailing = 72.691
P/E Forward = 35.8423
P/S = 7.0838
P/B = 4.7212
P/EG = 1.4766
Revenue TTM = 3.01b EUR
EBIT TTM = 563.3m EUR
EBITDA TTM = 886.6m EUR
Long Term Debt = 1.94b EUR (from longTermDebt, last quarter)
Short Term Debt = 314.8m EUR (from shortTermDebt, last quarter)
Debt = 2.57b EUR (from shortLongTermDebtTotal, last quarter) + Leases 171.0m
Net Debt = 2.37b EUR (calculated: Debt 2.57b - CCE 203.9m)
Enterprise Value = 23.7b EUR (21.3b + Debt 2.57b - CCE 203.9m)
Interest Coverage Ratio = 3.15 (Ebit TTM 563.3m / Interest Expense TTM 179.1m)
EV/FCF = 107.2x (Enterprise Value 23.7b / FCF TTM 220.7m)
FCF Yield = 0.93% (FCF TTM 220.7m / Enterprise Value 23.7b)
FCF Margin = 7.34% (FCF TTM 220.7m / Revenue TTM 3.01b)
Net Margin = 9.74% (Net Income TTM 292.6m / Revenue TTM 3.01b)
Gross Margin = 44.87% ((Revenue TTM 3.01b - Cost of Revenue TTM 1.66b) / Revenue TTM)
Gross Margin QoQ = 46.86% (prev 45.36%)
Tobins Q-Ratio = 2.99 (Enterprise Value 23.7b / Total Assets 7.92b)
Interest Expense / Debt = 6.96% (Interest Expense 179.1m / Debt 2.57b)
Taxrate = 28.54% (117.3m / 411.0m)
NOPAT = 402.5m (EBIT 563.3m * (1 - 28.54%))
Current Ratio = 1.16 (Total Current Assets 1.35b / Total Current Liabilities 1.17b)
Debt / Equity = 0.61 (Debt 2.57b / totalStockholderEquity, last quarter 4.24b)
Debt / EBITDA = 2.67 (Net Debt 2.37b / EBITDA 886.6m)
Debt / FCF = 10.74 (Net Debt 2.37b / FCF TTM 220.7m)
Total Stockholder Equity = 4.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.61% (Net Income 292.6m / Total Assets 7.92b)
RoE = 7.11% (Net Income TTM 292.6m / Total Stockholder Equity 4.12b)
RoCE = 9.30% (EBIT 563.3m / Capital Employed (Equity 4.12b + L.T.Debt 1.94b))
RoIC = 5.82% (NOPAT 402.5m / Invested Capital 6.92b)
WACC = 7.35% (E(21.3b)/V(23.9b) * Re(7.64%) + D(2.57b)/V(23.9b) * Rd(6.96%) * (1-Tc(0.29)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 11.76 | Cagr: 0.26%
[DCF] Terminal Value 73.10% ; FCFF base≈331.0m ; Y1≈290.3m ; Y5≈234.5m
[DCF] Fair Price = 14.34 (EV 3.76b - Net Debt 2.37b = Equity 1.39b / Shares 97.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 14.06 | EPS CAGR: 2.45% | SUE: -0.22 | # QB: 0
Revenue Correlation: 66.33 | Revenue CAGR: 2.83% | SUE: -0.85 | # QB: -1
EPS current Quarter (2026-09-30): EPS=1.18 | Chg30d=-0.12% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=4.99 | Chg30d=-0.07% | Revisions=+12% | GrowthEPS=+13.5% | GrowthRev=+5.4%
EPS next Year (2027-12-31): EPS=6.01 | Chg30d=+0.76% | Revisions=+57% | GrowthEPS=+20.4% | GrowthRev=+11.1%
[Analyst] Revisions Ratio: +13% (up=7, down=5)